Pharmaceutical composition for the treatment of inflammatory bowel disease
OwnerJean-Pierre Sachetto, William Jeffery Sandborn +1inventors
InventorsJean-Pierre Sachetto, William Jeffery Sandborn, William John Tremaine
Life of this patent
Estimating the term…
Abstract
A polysaccharide selected from xanthan gum and HPMC is used for the treatment or prophylaxis of IBD, especially Crohn's Disease, left-sided ulcerative colitis or pouchitis.
Claims20
A method for the treatment of inflammatory bowel disease (IBD) comprising contacting the diseased mucosa of the gastrointestinal tract with a therapeutic amount of a polysaccharide selected from the group consisting of xanthan gum and hydroxypropylmethylcellulose (HPMC) as the sole therapeutic agent.
A post-gastrically available delayed release oral (DRO) pharmaceutical composition for the treatment or prophylaxis of inflammatory bowel disease (IBD), said composition comprising as the sole therapeutically active ingredient a polysaccharide selected from the group consisting of xanthan gum and hydroxypropylmethylcellulose (HPMC) in an amount effective to treat IBD, together with a pharmaceutically acceptable carrier or vehicle, said composition being an enteric coated dosage form adapted to release its contents within the region of the jejunum to the colon.
A liquid enema composition for the treatment of inflammatory bowel disease (IBD), said composition comprising hydroxypropylmethylcellulose (HPMC) as the sole therapeutic active agent in an amount effective to treat inflammatory bowel disease, together with a pharmaceutically acceptable carrier or vehicle, said HPMC being present in a concentration of about 1 to about 20% w/w based on the weight of the composition, and in an amount of about 1 to 20 g per unit dose.
Dependencies are inferred from the claim text.